Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Antiviral COVID-19 drug shows no benefit for Long COVID

Summary by News Medical
Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.

2 Articles

News MedicalNews Medical
Center

Antiviral COVID-19 drug shows no benefit for Long COVID

Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.

·Mona Vale, Australia
Read Full Article
ME AssociationME Association

Antiviral COVID-19 medication shows no benefit for Long COVID - The ME Association

An article, titled ‘Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition […] The post Antiviral COVID-19 medication shows no benefit for Long COVID appeared first on The ME Association.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

News Medical broke the news in Mona Vale, Australia on Tuesday, September 1, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

United Kingdom icon

United Kingdom

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal